Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening-Reference-Cited by-同舟云学术

Cost-Benefit Analysis of Universal Tandem Mass Spectrometry for Newborn Screening

Published:2002-10-01 Issue:4 Volume:110 Page:781-786
ISSN:0031-4005
Container-title:Pediatrics
language:en
Short-container-title:

Author:

Schoen Edgar J.¹,Baker John C.¹,Colby Christopher J.²,To Trinh T.¹

Affiliation:

1. Department of Genetics, Kaiser Permanente Medical Center, Oakland, California

2. Division of Research, Kaiser Permanente Medical Care Program, Oakland, California

Abstract

Objective. To estimate potential costs and benefits of routinely using tandem mass spectrometry (MS/MS) to screen newborns for inborn errors of metabolism. Method. Analysis of costs and benefits resulting from use of MS/MS in screening of 32 000 newborn infants using data from the Kaiser Permanente Medical Care Program of Northern California plus other published data. Setting. A large health maintenance organization. Results. In the base scenario, the cost per quality-adjusted life year saved by MS/MS screening was $5827; in the least favorable scenario, this cost was $11 419, and in the most favorable scenario, $736. Conclusion. Costs per quality-adjusted life year saved by MS/MS screening for inborn errors of metabolism compare favorably with other mass screening programs, including those for breast and prostate cancer.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Link

https://publications.aap.org/pediatrics/article-pdf/110/4/781/1116058/pe1002000781.pdf

Reference44 articles.

1. Naylor EW, Chace DH. Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol.1999;14(suppl 1):S4–S8

2. Simonsen H, Jensen UG. Technical aspects of neonatal screening using tandem mass spectrometry. Report from the 4th meeting of the International Society for Neonatal Screening. Acta Paediatr Suppl.1999;432:52–54

3. Ciske JB, Hoffman G, Hanson K, et al. Newborn screening in Wisconsin: program overview and test addition. WMJ.2000;99:38–42

4. Muenzer J, Frazier DM, McCandless SE, et al. Incidence and follow-up evaluation of metabolic disorders detected by newborn screening in North Carolina using tandem mass spectrometry. MMWR Morb Mortal Wkly Rep.2001;50(RR03):23–34. Synopses of selected papers presented at the Tandem Mass Spectrometry for Metabolic Disease Screening Among Newborns Workshop, San Antonio, Texas, June 2000. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5003a2.htm. Accessed May 30, 2002

5. Zytkovicz TH, Johnson D, Rojas D, et al. Testing newborn specimens by tandem mass spectrometry: the first 16 months’ experience in the New England Program. MMWR Morb Mortal Wkly Rep.2001;50(RR03):23–34. Synopses of selected papers presented at the Tandem Mass Spectrometry for Metabolic Disease Screening Among Newborns Workshop, San Antonio, Texas, June 2000. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5003a2.htm. Accessed May 30, 2002

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation;HEALTH TECHNOL ASSES;2024

2. An Insight into Indonesia’s Challenges in Implementing Newborn Screening Programs and Their Future Implications;Children;2023-07-13

3. Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology;BMC Health Services Research;2022-08-15

4. Spectrum of Common and Rare Small Molecule Inborn Errors of Metabolism Diagnosed in a Tertiary Care Center of Maharashtra, India;Cureus;2022-07-21

5. Co-designed strategies for delivery of positive newborn bloodspot screening results to parents: the ReSPoND mixed-methods study;Health and Social Care Delivery Research;2022-07